Skip to main content
    P

    Pasithea Therapeutics Corp (KTTA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.41
    +0.00 (+0.17%)

    Market Cap: $14.16M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    58%(7/12)
    Avg Surprise
    -235.35%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.21
    Range$-0.21 - $-0.21
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.48+56.3%
    60d ago$-0.210.0%
    30d ago$-0.210.0%
    7d ago$-0.210.0%
    Current$-0.21
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.06
    Range$0.06 - $0.06
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.06---
    Sep 26EST
    		-$-0.21---
    Jun 26
    Reported Aug 14
    		$-0.16$-0.16+0.00%Beat+75.8%
    Mar 26
    Reported May 15
    		$-0.12N/A+73.33%Beat+92.5%
    Dec 25
    Reported Feb 25
    		$-0.89$-0.18-394.44%Miss+64.8%
    Sep 25
    Reported Nov 13
    		$-0.41N/AN/ABeat+85.7%
    Jun 25
    Reported Aug 14
    		$-0.66$0.00N/AMiss+82.2%
    Mar 25
    Reported May 15
    		$-1.61N/AN/ABeat+56.5%
    Dec 24
    Reported Mar 24
    		$-2.53N/AN/ABeat+47.8%
    Sep 24
    Reported Nov 13
    		$-2.87N/AN/ABeat-1900.7%
    Jun 24
    Reported Aug 13
    		$-3.71N/AN/ABeat-30.5%
    Mar 24
    Reported May 14
    		$-3.70N/AN/ABeat-49.9%
    Dec 23
    Reported Mar 28
    		$-4.85$-0.19-2450.84%Miss-2592.6%
    Sep 23
    Reported Dec 29
    		$-0.14$-0.18+20.22%Beat+95.5%
    Jun 23
    Reported Aug 11
    		$-2.84$-3.40+16.47%Beat-8.0%
    Mar 23
    Reported May 12
    		$-2.47$-3.40+27.35%Beat-18.2%
    Dec 22
    Reported Mar 30
    		$-0.18$-0.18+0.00%Beat-250.0%
    Sep 22
    Reported Nov 14
    		$-3.20$-2.80-14.29%Miss-2566.7%
    Jun 22
    Reported Aug 15
    		$-2.63$-2.20-19.55%Miss-5160.0%
    Mar 22
    Reported May 16
    		$-2.09$-0.40-422.50%Miss-2272.3%
    Dec 21
    Reported Mar 30
    		$0.12$-0.05+340.00%Beat+273.7%
    Sep 21
    Reported Nov 18
    		$-0.12N/AN/ABeat-6215.8%
    Jun 21
    Reported Sep 16
    		$-0.05$0.00N/AMiss-
    Mar 21
    Reported Jun 30
    		$-0.09$0.00N/AMiss-
    Dec 20
    Reported Mar 31
    		$-0.07$0.00N/AMiss-
    Jun 20
    Reported Sep 30
    		$-0.00$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.26EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-65.50%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio26.25xQuick Ratio26.25x
    Trading Statistics
    Beta0.34Avg Volume134.20K
    52-Week High$2.0652-Week Low$0.28

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.44
    SMA 20$0.47
    SMA 50$0.50
    SMA 200$0.67
    EMA 10$0.44
    EMA 20$0.46
    EMA 50$0.49
    EMA 200$0.63

    MACD

    Line: -0.03Signal: -0.02Hist: -0.01

    ADX

    ADX: 20.7+DI: 8.5-DI: 24.1

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$0.48

    Bollinger Bands

    Upper Band$0.54
    Lower Band$0.40
    %B Position3047%(Upper)
    Band Width0.07

    RSI (14-Day)

    Neutral
    30.8

    Momentum Oscillators

    Stoch %K17.9
    Stoch %D16.1
    Williams %R-78.6
    ROC (10d)-16.2%
    Momentum-0.08
    CCI (20d)-141.7
    MFI (14d)18.8

    Volatility Measures

    ATR (14d)$0.04(8.7%)
    StdDev (20d)0.04
    Hist Vol44.8%(High)

    Volume Flow

    VWAP$0.42
    OBV598.8M
    AD Line-277.3M
    CMF (20d)-0.073

    Volume Metrics

    Avg Vol (20d)131.7K
    Vol Ratio0.2x(Low)
    VWMA (20d)$0.47

    Pivot Points

    R3$0.50
    R2$0.47
    R1$0.44
    Pivot Point$0.41
    S1$0.38
    S2$0.35
    S3$0.32

    Advanced Oscillators

    TSI-28.15
    Ultimate Osc35.1
    KST-141.71

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$649,028$0$0$0$976,306$0
    Cost of Revenue$0$0$157,962$0$0$0$162,258$0$0$0$162,221$0
    Gross Profit$0$0$-157,962$0$0$0$-162,258$0$0$0$-162,221$0
    Operating Expenses$5.71M$4.88M$10.26M$3.11M$3.81M$3.68M$3.26M$3.00M$3.95M$4.04M$5.15M$3.79M
    R&D$3.69M$2.94M$2.74M$1.36M$2.15M$1.73M$1.51M$1.58M$2.36M$1.75M$3.35M$1.62M
    SG&A$2.03M$1.93M$7.51M$1.75M$1.66M$1.95M$1.75M$1.42M$1.59M$2.29M$1.80M$2.16M
    Operating Income$-5,713,282$-4,876,644$-10,256,162$-3,110,055$-3,810,899$-3,680,179$-3,259,550$-3,004,604$-3,945,034$-4,040,774$-5,148,782$-3,789,326
    Interest Income$410,416$450,338$182,128$43,396$54,424$47,245$80,483$75,076$114,407$153,218$0$131,740
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-5,273,852$-2,869,482$-10,110,868$-3,037,420$-3,716,157$-3,563,238$-3,177,661$-2,999,834$-3,866,249$-3,860,840$-5,031,264$-3,612,590
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-5,273,852$-2,869,482$-10,110,868$-3,037,420$-3,716,157$-3,563,238$-3,177,661$-2,999,834$-3,866,249$-3,860,840$-5,048,159$-3,612,590
    EBITDA$-5,526,727$-3,162,279$-10,128,284$-2,899,224$-3,609,491$-3,440,950$-3,100,656$-2,907,883$-3,818,400$-3,851,800$-5,152,671$-3,582,074
    EBIT$-5,684,268$-3,319,820$-10,285,825$-3,080,816$-3,770,581$-3,603,312$-3,262,914$-3,070,140$-3,980,656$-4,014,058$-5,314,892$-3,744,330
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KTTA

    News

    Pasithea Therapeutics Corp Share Price - KTTA, RNS News, Articles, Quotes, & Charts (NASDAQ:KTTA)

    This article provides a company overview for Pasithea Therapeutics Corp (NASDAQ:KTTA), a biotechnology firm focused on psychiatric and neurological disorders. It lists key financial data...

    Proactive financial news•10/6/26•Neutral

    Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

    Pasithea Therapeutics (Nasdaq: KTTA) will present initial clinical data from its ongoing Phase 1/1b trial of PAS-004 in adult NF1 patients at the 2026 European Neurofibromatosis Conference in Vienna...

    Yahoo Finance•9/14/26•Somewhat-Bullish

    Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

    Pasithea Therapeutics (Nasdaq: KTTA) will present initial clinical data from its Phase 1/1b trial of PAS-004 in adults with NF1 at the 2026 European Neurofibromatosis Conference. The data...

    Investing News Network•9/14/26•Somewhat-Bullish

    Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

    Pasithea Therapeutics Corp. announced its participation in two investor conferences in September 2026. Management will hold one-on-one meetings at the 12th Annual Cantor Global Healthcare Conference from September 9-11...

    Yahoo! Finance Canada•9/4/26•Somewhat-Bullish

    Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

    Pasithea Therapeutics (NASDAQ: KTTA) announced its participation in two investor conferences in September 2026...

    Investing News Network•9/3/26•Somewhat-Bullish

    KTTA Valuation and Fair Value

    P/E
    -0.3x
    P/B
    0.3x
    See GNG's fair value

    KTTA Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -65.5%

    KTTA Competitors

    CompanyTicker
    Dare Bioscience IncDARE
    Estrella Immunopharma Inc.ESLA
    IRIDEX CorporationIRIX
    SINTX Technologies IncSINT
    Tscan Therapeutics IncTCRX
    Citius Pharmaceuticals IncCTXR
    Marker Therapeutics IncMRKR
    Vyome Holdings, Inc.HIND

    Sector: Healthcare

    KTTA Bull Case vs Bear Case

    Bull case

    • KTTA grew quarterly revenue 1498.0% year over year.

    KTTA Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -386.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.21
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About KTTA

    Does KTTA pay dividends?

    Pasithea Therapeutics Corp (KTTA) does not currently pay a regular dividend.

    What is KTTA's market cap?

    Pasithea Therapeutics Corp (KTTA) has a market capitalization of $14.16M with a current stock price of $0.41.

    Related stocks

    Sector: Healthcare

    All stocks starting with K

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In